BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37113048)

  • 21. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-grade CIN on cervical biopsy and predictors of the subsequent cone histology results in women undergoing immediate conization.
    Giannella L; Mfuta K; Gardini G; Rubino T; Fodero C; Prandi S
    Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():68-74. PubMed ID: 25656975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Burden of CIN2+ diagnoses and conizations in women aged 18-45 years-a retrospective secondary data analysis of German statutory health insurance claims data.
    Reuschenbach M; Stephan AJ; Saxena K; Prabhu VS; Jacob C; Schneider KM; Greiner W; Wölle R; Hampl M
    Arch Gynecol Obstet; 2022 Dec; 306(6):2077-2092. PubMed ID: 35420356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening.
    Sargent A; Fletcher S; Bray K; Kitchener HC; Crosbie EJ
    BMJ Open; 2019 Apr; 9(4):e025388. PubMed ID: 31036707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia.
    Spinillo A; Dominoni M; Boschi AC; Cesari S; Fiandrino G; Gardella B
    Gynecol Oncol; 2020 Dec; 159(3):630-635. PubMed ID: 33041069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HPV-negative high-grade cervical precancerous lesions or invasive cancer in China: A post hoc analysis of a multicentric clinical study.
    Bao H; Zhao Y; Zhang X; Bi H; Cong S; Fang L; Wang HJ; Wang L
    Int J Gynaecol Obstet; 2023 Apr; 161(1):159-167. PubMed ID: 36444986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders.
    Gök M; Heideman DA; van Kemenade FJ; de Vries AL; Berkhof J; Rozendaal L; Beliën JA; Overbeek L; Babović M; Snijders PJ; Meijer CJ
    Eur J Cancer; 2012 Aug; 48(12):1799-808. PubMed ID: 22172570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.
    Zorzi M; Frayle H; Rizzi M; Fedato C; Rugge M; Penon MG; Bertazzo A; Callegaro S; Campagnolo M; Ortu F; Del Mistro A;
    BJOG; 2017 Sep; 124(10):1585-1593. PubMed ID: 28120382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer.
    Jeronimo J; Bansil P; Valdez M; Kang LN; Zhao FH; Qiao YL; Chen W; Zhang X; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    J Low Genit Tract Dis; 2015 Jul; 19(3):220-3. PubMed ID: 25279978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment.
    Stanczuk GA; Currie H; Baxter G; Foster A; Gibson L; Graham C; Cuschieri K
    J Clin Pathol; 2015 Jul; 68(7):567-70. PubMed ID: 25878328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
    Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
    BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.